STIM on Nasdaq
Neuronetics, Inc.
Logo: Gusdavinci, CC BY-SA 4.0, via Wikimedia Commons5
American neuromodulation company
Neuronetics is a Malvern, PA based, publicly traded company incorporated in Delaware in April 2003, that develops non-invasive treatments for psychiatric disorders that have shown resistance or lack of improvement using traditional medicine. The treatments are based upon neuromodulation technology.3 From Wikipedia, CC BY-SA 4.0
Price unavailable
Last updated Oct 19, 2026.
Overview
2003Founded1
Compare with InfuSystem Holdings, Inc, Xtant Medical (United States) or Heartflow, Inc., or pick any stock.
- TickerSTIM on Nasdaq1
- IndustrySurgical & Medical Instruments & Apparatus1
- HeadquartersMalvern1
- Websitewww.neuronetics.com
- Legal formDelaware corporation1
- Incorporated inDE6
- Business address3222 Phoenixville Pike, Malvern, Pa 193556
- Filer categoryNon-accelerated filer, Smaller reporting company6
- LEI549300T0911ILTTG7P064
- StatusActive4
- LEI statusLapsed (not renewed)4
- Registered addressC/O The Corporation Trust Company, 19801 Wilmington, United States4
- Registered withDivision of Corporations, Department of State, 34107434
See how the biggest companies compare on our leaderboards
Neuronetics is a Malvern, PA based, publicly traded company incorporated in Delaware in April 2003, that develops non-invasive treatments for psychiatric disorders that have shown resistance or lack of improvement using traditional medicine. The treatments are based upon neuromodulation technology.3
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
48.5%Gross margin7
-21.1%Operating margin7
-26.1%Net margin7
99.2%Revenue growth, 20257
-174.3%Return on equity7
2.94×Debt to equity7
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Products and services
Service brought in 58% of the revenue Neuronetics, Inc. broke down this way in fiscal 2025.
Products and services by year
| Products and services | 2023 | 2024 | 2025 |
|---|---|---|---|
| Service | $4.4M | $87.0M | |
| Product | $71.3M | $70.4M | $62.2M |
Business segments
Clinical Services brought in 58% of the revenue Neuronetics, Inc. broke down this way in fiscal 2025.
Business segments by year
| Business segments | 2023 | 2024 | 2025 |
|---|---|---|---|
| Clinical Services | $4.4M | $87.0M | |
| Medical Device | $71.3M | $70.4M | $62.2M |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue52¢$76.8M
- Research and development4¢$6.6M
- Other costs44¢$65.7M
Out of $149.2M in revenue.7 The company lost money this year.
Financial statements
Every line of the income statement as filed: the last 3 fiscal years, latest first.7
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Total Revenues | $149.2M | $74.9M | $71.3M |
| Total Cost of revenues | $76.8M | $20.7M | $19.6M |
| Gross profit | $72.3M | $54.2M | $51.7M |
| Sales and marketing | $47.5M | $45.6M | $47.3M |
| General and administrative | $49.7M | $30.3M | $25.4M |
| Research and development | $6.6M | $12.8M | $9.5M |
| Total operating expenses | $103.7M | $88.7M | $82.3M |
| Loss from operations | -$31.4M | -$34.6M | -$30.6M |
| Interest expense | $8.4M | $7.3M | $5.4M |
| Loss on extinguishment of debt | $4.4M | ||
| Other income, net | -$716.0K | -$2.5M | -$5.8M |
| Net loss | -$39.1M | -$43.7M | -$30.2M |
| Less: Net loss attributable to non-controlling interest | -$137.0K | -$19.0K | |
| Net loss attributable to Neuronetics stockholders' | -$39.0M | -$43.7M | -$30.2M |
| Net loss per share of common stock outstanding, basic attributable to Neuronetics stockholders' | -$0.59 | -$1.38 | -$1.05 |
| Net loss per share of common stock outstanding, diluted attributable to Neuronetics stockholders' | -$0.59 | -$1.38 | -$1.05 |
| Weighted average common shares outstanding, basic (in shares) | 66.0M shares | 31.7M shares | 28.7M shares |
| Weighted average common shares outstanding, diluted (in shares) | 66.0M shares | 31.7M shares | 28.7M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.7
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $28.1M | $18.5M | $59.7M | |
| Restricted cash and cash equivalents | $6.0M | $1.0M | ||
| Accounts receivable, net of allowance of credit losses for $1,043 and $1,930 as of December 31, 2025 and December 31, 2024, respectively | $16.5M | $23.4M | ||
| Inventory | $4.3M | $4.2M | ||
| Current portion of net investments in sales-type leases | $225.0K | $206.0K | ||
| Current portion of prepaid commission expense | $3.0M | $3.1M | ||
| Current portion of notes receivable | $424.0K | $930.0K | ||
| Prepaid expenses and other current assets | $2.9M | $6.8M | ||
| Total current assets | $61.6M | $58.1M | ||
| Property and equipment, net | $4.5M | $6.2M | ||
| Goodwill | $23.6M | $18.6M | ||
| Intangible assets, net | $18.1M | $19.6M | ||
| Operating lease right-of-use assets | $23.6M | $27.1M | ||
| Net investments in sales-type leases | $98.0K | $86.0K | ||
| Prepaid commission expense | $8.0M | $8.9M | ||
| Long-term notes receivable | $151.0K | $295.0K | ||
| Other assets | $2.0M | $1.9M | ||
| Total assets | $141.6M | $140.9M | ||
| Accounts payable | $10.7M | $11.1M | ||
| Accrued expenses | $12.3M | $12.8M | ||
| Current portion of deferred revenue | $753.0K | $974.0K | ||
| Deferred and contingent consideration | $500.0K | $1.0M | ||
| Other payables | $652.0K | $605.0K | ||
| Current portion of operating lease liabilities | $5.6M | $4.8M | ||
| Total current liabilities | $30.5M | $31.3M | ||
| Long-term debt, net | $65.8M | $55.2M | ||
| Deferred revenue | $48.0K | $2.0K | ||
| Operating lease liabilities | $18.9M | $22.7M | ||
| Total liabilities | $115.3M | $109.1M | ||
| Common stock, $0.01 par value: 250,000 shares authorized; 68,994 and 55,679 shares issued and outstanding on December 31, 2025 and 2024, respectively | $690.0K | $557.0K | ||
| Additional paid-in capital | $480.5M | $446.9M | ||
| Accumulated deficit | -$458.8M | -$419.8M | ||
| Total Stockholders' equity | $22.4M | $27.7M | ||
| Non-controlling interest | $3.9M | $4.1M | ||
| Total equity | $26.2M | $31.8M | $34.2M | $57.1M |
| Total liabilities and equity | $141.6M | $140.9M | ||
| Allowance of credit losses | $1.0M | $1.9M | $795.0K | $1.6M |
| Preferred stock, par value (in dollars per share) | $0.01 | $0.01 | ||
| Preferred stock, shares authorized (in shares) | 10.0M shares | 10.0M shares | ||
| Preferred stock, shares issued (in shares) | 0 shares | 0 shares | ||
| Preferred stock, shares outstanding (in shares) | 0 shares | 0 shares | ||
| Common stock, par value (in dollars per share) | $0.01 | $0.01 | ||
| Common stock, shares authorized (in shares) | 250.0M shares | 250.0M shares | ||
| Common stock, shares issued (in shares) | 69.0M shares | 55.7M shares | ||
| Common stock, shares outstanding (in shares) | 69.0M shares | 55.7M shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $28.1M | $18.5M | $59.7M | |
| Restricted cash and cash equivalents | $6.0M | $1.0M | ||
| Accounts receivable, net of allowance of credit losses for $1,043 and $1,930 as of December 31, 2025 and December 31, 2024, respectively | $16.5M | $23.4M | ||
| Inventory | $4.3M | $4.2M | ||
| Current portion of net investments in sales-type leases | $225.0K | $206.0K | ||
| Current portion of prepaid commission expense | $3.0M | $3.1M | ||
| Current portion of notes receivable | $424.0K | $930.0K | ||
| Prepaid expenses and other current assets | $2.9M | $6.8M | ||
| Total current assets | $61.6M | $58.1M | ||
| Property and equipment, net | $4.5M | $6.2M | ||
| Goodwill | $23.6M | $18.6M | ||
| Intangible assets, net | $18.1M | $19.6M | ||
| Operating lease right-of-use assets | $23.6M | $27.1M | ||
| Net investments in sales-type leases | $98.0K | $86.0K | ||
| Prepaid commission expense | $8.0M | $8.9M | ||
| Long-term notes receivable | $151.0K | $295.0K | ||
| Other assets | $2.0M | $1.9M | ||
| Total assets | $141.6M | $140.9M | ||
| Accounts payable | $10.7M | $11.1M | ||
| Accrued expenses | $12.3M | $12.8M | ||
| Current portion of deferred revenue | $753.0K | $974.0K | ||
| Deferred and contingent consideration | $500.0K | $1.0M | ||
| Other payables | $652.0K | $605.0K | ||
| Current portion of operating lease liabilities | $5.6M | $4.8M | ||
| Total current liabilities | $30.5M | $31.3M | ||
| Long-term debt, net | $65.8M | $55.2M | ||
| Deferred revenue | $48.0K | $2.0K | ||
| Operating lease liabilities | $18.9M | $22.7M | ||
| Total liabilities | $115.3M | $109.1M | ||
| Common stock, $0.01 par value: 250,000 shares authorized; 68,994 and 55,679 shares issued and outstanding on December 31, 2025 and 2024, respectively | $690.0K | $557.0K | ||
| Additional paid-in capital | $480.5M | $446.9M | ||
| Accumulated deficit | -$458.8M | -$419.8M | ||
| Total Stockholders' equity | $22.4M | $27.7M | ||
| Non-controlling interest | $3.9M | $4.1M | ||
| Total equity | $26.2M | $31.8M | $34.2M | $57.1M |
| Total liabilities and equity | $141.6M | $140.9M | ||
| Allowance of credit losses | $1.0M | $1.9M | $795.0K | $1.6M |
| Preferred stock, par value (in dollars per share) | $0.01 | $0.01 | ||
| Preferred stock, shares authorized (in shares) | 10.0M shares | 10.0M shares | ||
| Preferred stock, shares issued (in shares) | 0 shares | 0 shares | ||
| Preferred stock, shares outstanding (in shares) | 0 shares | 0 shares | ||
| Common stock, par value (in dollars per share) | $0.01 | $0.01 | ||
| Common stock, shares authorized (in shares) | 250.0M shares | 250.0M shares | ||
| Common stock, shares issued (in shares) | 69.0M shares | 55.7M shares | ||
| Common stock, shares outstanding (in shares) | 69.0M shares | 55.7M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 3 fiscal years, latest first.7
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net loss | -$39.1M | -$43.7M | -$30.2M |
| Depreciation and amortization | $3.5M | $2.1M | $2.0M |
| Capitalized software impairment | $4.0M | ||
| Allowance for credit losses | $587.0K | $2.1M | $390.0K |
| Inventory impairment | $388.0K | $626.0K | $1.9M |
| Share-based compensation | $6.8M | $5.6M | $7.3M |
| Non-cash interest expense | $824.0K | $771.0K | $634.0K |
| Loss on extinguishment of debt | $4.4M | ||
| Loss on disposal of property and equipment | $72.0K | $28.0K | |
| Accounts receivable, net | $3.5M | -$3.7M | -$8.8M |
| Inventory | -$395.0K | $3.1M | -$1.1M |
| Net investments in sales-type leases | -$31.0K | $997.0K | $1.2M |
| Prepaid commission expense | $958.0K | -$1.1M | -$1.3M |
| Prepaid expenses and other assets | $4.7M | -$1.2M | -$2.8M |
| Accounts payable | -$1.8M | -$2.0M | $2.0M |
| Accrued expenses | -$502.0K | -$2.1M | -$2.2M |
| Other liabilities | $257.0K | -$66.0K | |
| Deferred revenue | -$175.0K | -$843.0K | -$989.0K |
| Net Cash used in Operating activities | -$20.4M | -$31.0M | -$32.0M |
| Purchases of property and equipment and capitalized software | -$801.0K | -$1.5M | -$2.4M |
| Cash paid for acquisition, net of cash and restricted cash acquired | -$2.6M | ||
| Repayment of notes receivable | $1.6M | $1.0M | |
| Net Cash used in Investing activities | -$801.0K | -$2.4M | -$1.3M |
| Payments of debt issuance costs | -$168.0K | -$2.6M | -$1.1M |
| Proceeds from issuance of long-term debt | $10.0M | $57.5M | $25.0M |
| Repayment of promissory note | -$211.0K | ||
| Repayment of deferred and contingent consideration | -$500.0K | ||
| Proceeds from issuance of warrants | $2.5M | ||
| Repayment of long-term debt | -$60.0M | -$1.2M | |
| Payment for debt extinguishment cost | -$4.2M | ||
| Distribution to non-controlling interest | -$94.0K | ||
| Proceeds from exercises of stock options | $13.0K | $1.0K | $1.0K |
| Net Cash provided by (used in) Financing activities | $35.9M | -$6.8M | $22.7M |
| Net increase (decrease) in Cash, Cash equivalents and Restricted cash | $14.7M | -$40.2M | -$10.7M |
| Cash paid for interest | $7.6M | $6.5M | $4.8M |
| Transfer of inventory to property and equipment | $106.0K | $92.0K | $210.0K |
| Purchases of property and equipment and capitalized software in accounts payable and accrued expenses | $83.0K | $13.0K | $239.0K |
| Reduction of accounts receivable in current and long-term notes receivable | $606.0K | $6.5M |
No quarter-by-quarter statement was filed.
Leadership
Who has led Neuronetics, Inc., and when. Pick a name to see everywhere that person has worked.
Chief financial officer
20052010201520202025
- Chief executive officerDaniel L. Reuvers Mar 23, 2026 to now15
- Chief executive officerKeith J. Sullivan Jul 16, 2020 to Mar 23, 202616
- Chief executive officerChristopher Thatcher Jun 27, 2018 to Mar 4, 202017
- PresidentDaniel L. Reuvers Mar 23, 2026 to now15
- PresidentKeith J. Sullivan Jul 16, 2020 to Mar 23, 202616
- PresidentChristopher Thatcher Jun 27, 2018 to Mar 4, 202017
- Chief financial officerNir Naor Jul 23, 2026 to now18
- Chief financial officerSteven Pfanstiel Jul 15, 2025 to Jul 23, 202619
- Chief financial officerStephen Furlong Jul 24, 2019 to Jul 15, 202520
- Chief financial officerPeter Donato Jun 27, 2018 to May 14, 201921
Board members and other officers (20)
- Interim PAOFrancis X. Brown Iii. May 13, 2026 to now22
- EVP & Gen. Manager, GreenbrookCory Anderson Jul 13, 2026 to now23
- Sr. VP, GC, CCO and SecretaryWilliam Andrew Macan Jan 22, 2020 to now24
- Chief Commercial OfficerDaniel Guthrie Jun 27, 2018 to May 26, 202025
- VP of Commercial AccessYelena Tropsha Jun 27, 2018 to Mar 11, 202026
- Board memberAvinash Amin Dec 19, 2024 to now27
- Board memberSasha Cucuz Dec 19, 2024 to now28
- Board memberJoseph H. Capper Jan 4, 2023 to May 30, 202329
- Board memberRobert Cascella Apr 5, 2021 to now30
- Board memberMegan Rosengarten Aug 6, 2021 to now31
- Board memberBruce Joseph Shook Jun 26, 2020 to May 31, 202232
- Board memberKeith J. Sullivan Jul 16, 2020 to now16
- Board memberCheryl R. Blanchard Feb 15, 2019 to May 28, 202033
- Board memberSheryl L. Conley Nov 1, 2019 to now34
- Board memberBrian E. Farley Jun 27, 2018 to Aug 7, 202035
- Board memberChristopher Thatcher Jun 27, 2018 to Mar 4, 202017
- Board memberGlenn P. Muir Jun 27, 2018 to now36
- Board memberWilfred E. Jaeger Jun 27, 2018 to May 30, 202337
- Board memberStephen M. Campe Jun 28, 2018 to Jan 6, 202038
- General counselWilliam Andrew Macan Jan 24, 2023 to now39
Former names
- NEURONETICS INCApr 15, 2003 to Aug 16, 20066
Timeline
Filings
445 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 86 major events, 191 insider forms, 44 large holders, 104 other. The latest 20:
- Aug 24, 2026SCHEDULE 13D/A EDGAR
- Aug 19, 2026144 EDGAR
- Aug 18, 2026144 EDGAR
- Aug 17, 20268-K EDGAR
- Aug 17, 20264 OWNERSHIP DOCUMENT EDGAR
- Aug 14, 2026SCHEDULE 13G EDGAR
- Aug 11, 2026S-8 EDGAR
- Aug 11, 20268-K EDGAR
- Aug 11, 202610-Q EDGAR
- Aug 4, 2026SCHEDULE 13D/A EDGAR
- Jul 23, 20264 EDGAR
- Jul 23, 20263 EDGAR
- Jul 20, 20268-K EDGAR
- Jul 15, 20264 OWNERSHIP DOCUMENT EDGAR
- Jul 13, 20263 EDGAR
- Jun 23, 20268-K EDGAR
- Jun 17, 20264 EDGAR
- Jun 17, 20264 EDGAR
- Jun 8, 2026144 EDGAR
- May 29, 20264 EDGAR
The 445 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
166 open-market trades by officers, directors and large owners since October 2021: 66 buys and 100 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Aug 14, 2026 | Chernett Jorey10% owner | Buy | 14,000 | $3.16 | $44.2K | Form 4 |
| Jul 14, 2026 | Chernett Jorey10% owner | Buy | 35,000 | $1.78 | $62.3K | Form 4 |
| May 19, 2026 | Chernett Jorey10% owner | Buy | 100,000 | $1.17 | $117.0K | Form 4 |
| May 12, 2026 | Chernett Jorey10% owner | Buy | 475,000 | $1.34 | $636.5K | Form 4 |
| Apr 21, 2026 | Chernett Jorey10% owner | Buy | 100,000 | $1.51 | $151.0K | Form 4 |
| Apr 20, 2026 | Chernett Jorey10% owner | Buy | 100,000 | $1.58 | $158.0K | Form 4 |
| Mar 30, 2026 | Chernett Jorey10% owner | Buy | 385,442 | $1.25 | $481.8K | Form 4 |
| Mar 27, 2026 | Chernett Jorey10% owner | Buy | 500,000 | $1.35 | $675.0K | Form 4 |
| Mar 26, 2026 | Chernett Jorey10% owner | Buy | 25,000 | $1.44 | $36.0K | Form 4 |
| Mar 25, 2026 | Chernett Jorey10% owner | Buy | 125,000 | $1.40 | $175.0K | Form 4 |
| Mar 20, 2026 | Chernett Jorey10% owner | Buy | 169,472 | $1.41 | $239.0K | Form 4 |
| Mar 19, 2026 | Pfanstiel StevenFormer EVP, CFO and Treasurer | Sale | 8,569 | $1.34 | $11.5K | Form 4 |
| Mar 19, 2026 | Pfanstiel StevenFormer EVP, CFO and Treasurer | Sale | 16,431 | $1.34 | $22.0K | Form 4 |
| Mar 19, 2026 | Sullivan Keith J | Sale | 46,289 | $1.34 | $62.0K | Form 4 |
| Mar 19, 2026 | MACAN WILLIAM ANDREWEVP, CLO and CS | Sale | 16,005 | $1.34 | $21.4K | Form 4 |
| Mar 19, 2026 | Chernett Jorey10% owner | Buy | 450,000 | $1.33 | $598.5K | Form 4 |
| Mar 18, 2026 | Chernett Jorey10% owner | Buy | 607,400 | $1.35 | $820.0K | Form 4 |
| Mar 17, 2026 | Chernett Jorey10% owner | Buy | 531,000 | $1.16 | $616.0K | Form 4 |
| Mar 4, 2026 | MACAN WILLIAM ANDREWEVP, CLO and CS | Sale | 609 | $1.34 | $816 | Form 4 |
| Feb 26, 2026 | MACAN WILLIAM ANDREWEVP, CLO and CS | Sale | 3,427 | $1.35 | $4.6K | Form 4 |
All 166 trades can be filtered by person here when JavaScript is on.
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- Jorey ChernettSCHEDULE 13D/A, 8 filings Nov 24, 2025 to Aug 24, 202640
- Point72 Asset Management, L.P.SCHEDULE 13G, 1 filing Aug 14, 202641
- Parian Ultreia LPSCHEDULE 13G, 1 filing Mar 17, 202642
- Madryn Asset Management, LPSCHEDULE 13D/A, 3 filings Dec 17, 2024 to Mar 4, 202643
- Kent Lake PR LLCSCHEDULE 13G/A, 2 filings Nov 14, 2024 to Feb 14, 202544
- CANNELL CAPITAL LLCSC 13G/A, 8 filings Feb 14, 2022 to Nov 14, 202445
- Divisadero Street Capital Management, LPSC 13G/A, 2 filings Apr 1, 2024 to Nov 14, 202446
- Parian Global Management LPSCHEDULE 13G/A, 3 filings Feb 9, 2022 to Nov 14, 202447
- Archon Capital Management LLCSC 13G/A, 5 filings Feb 14, 2022 to Aug 14, 202448
- Kent Lake Capital LLCSC 13G, 4 filings Feb 14, 2022 to Jun 28, 202449
- SCHRODER INVESTMENT MANAGEMENT NORTH AMERICA INC/ DESC 13G, 2 filings Feb 9, 2022 to Feb 10, 202350
- INTERWEST PARTNERS VIII LPSC 13G/A, 1 filing Feb 14, 202251
- Granite Point Capital Management, L.P.SC 13G/A, 1 filing Jan 26, 202252
- Investor Growth Capital Holding LLCSC 13G/A, 1 filing Jan 26, 202253
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 87. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| Madryn Asset Management, LP | 18,540,488 | $24.1M | 65.3% | +64,595 |
| UBS Group AG | 2,279,099 | $3.0M | 0.0% | −591,499 |
| Wexford Capital LP | 2,002,625 | $2.6M | 0.4% | +1,301,664 |
| FourWorld Capital Management LLC | 1,744,142 | $2.3M | 2.6% | +254,820 |
| Lane Generational LLC | 1,633,372 | $2.1M | 1.9% | −141,252 |
| Vanguard Capital Management LLC | 1,507,097 | $2.0M | 0.0% | −540,878 |
| Masters Capital Management LLC | 1,000,000 | $1.3M | 0.2% | No change |
| AdvisorShares Investments LLC | 742,795 | $965.6K | 0.1% | +125,602 |
| Ikarian Capital, LLC | 701,182 | $911.5K | 0.1% | No change |
| BlackRock, Inc. | 596,622 | $775.6K | 0.0% | −1,721,915 |
| HighTower Advisors, LLC | 563,741 | $732.9K | 0.0% | +1,371 |
| Marshall Wace, Llp | 485,692 | $631.4K | 0.0% | New |
| Geode Capital Management, LLC | 458,474 | $596.2K | 0.0% | −500,515 |
| Citadel Advisors LLC | 421,903 | $548.5K | 0.0% | +345,306 |
| Dauntless Investment Group, LLC | 369,187 | $479.9K | 0.8% | +99,979 |
| State Street Corp | 290,299 | $377.4K | 0.0% | −552,248 |
| Centiva Capital, LP | 285,913 | $371.7K | 0.0% | +116,594 |
| Vanguard Fiduciary Trust Co | 264,734 | $344.2K | 0.0% | +6,700 |
| Goldman Sachs Group Inc | 264,088 | $343.3K | 0.0% | +30,498 |
| JBF Capital, Inc. | 233,166 | $303.1K | 0.0% | No change |
| XTX Topco Ltd | 220,323 | $286.4K | 0.0% | +74,168 |
| Millennium Management LLC | 199,450 | $259.3K | 0.0% | New |
| Boothbay Fund Management, LLC | 189,263 | $246.0K | 0.0% | No change |
| Susquehanna International Group, Llp | 185,753 | $241.5K | 0.0% | +99,272 |
| Jane Street Group, LLC | 185,250 | $240.8K | 0.0% | +168,676 |
13F reports cover disclosed long positions in U.S. stocks only.
Links
- Websitewww.neuronetics.com1
- LinkedInwww.linkedin.com/company/1470381
- WikipediaNeuronetics
- WikidataQ7002474
- SEC EDGARCIK 1227636
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1WikidataNeuronetics, Inc. on Wikidata
- 2
- 3WikipediaNeuronetics, Inc. on Wikipedia
- 4
- 5Wikimedia CommonsNeuronetics, Inc. logo by Gusdavinci, CC BY-SA 4.0
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18SEC EDGARNir Naor, Chief financial officer
- 19
- 20
- 21
- 22SEC EDGARFrancis X. Brown Iii., Interim PAO
- 23
- 24
- 25
- 26
- 27SEC EDGARAvinash Amin, Board member
- 28SEC EDGARSasha Cucuz, Board member
- 29SEC EDGARJoseph H. Capper, Board member
- 30SEC EDGARRobert Cascella, Board member
- 31SEC EDGARMegan Rosengarten, Board member
- 32SEC EDGARBruce Joseph Shook, Board member
- 33SEC EDGARCheryl R. Blanchard, Board member
- 34SEC EDGARSheryl L. Conley, Board member
- 35SEC EDGARBrian E. Farley, Board member
- 36SEC EDGARGlenn P. Muir, Board member
- 37SEC EDGARWilfred E. Jaeger, Board member
- 38SEC EDGARStephen M. Campe, Board member
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53